{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T13:21:40Z","timestamp":1793020900938,"version":"4.5.0"},"reference-count":42,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,8,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Targeted therapy (TT) with BRAF\/MEK inhibitors has emerged as a potential treatment in papillary craniopharyngiomas (PCPs). However, standardized data on large cohorts are lacking. Our study aimed to assess real-life efficacy and safety of BRAF\/MEK inhibition in patients with PCPs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>Retrospective French multicenter study involving BRAF V600E\u2013mutated PCP patients, treated with BRAF\/MEK inhibitor combination dabrafenib and trametinib, from April 2019 to July 2023.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Objective response and clinical and safety outcomes were assessed after 3 months and at the last available follow-up during TT.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Sixteen patients (8 females, mean age 50.5 \u00b1 15.75 years), receiving either neoadjuvant therapy (NEO) for non-resectable tumors (n = 6), post-surgical adjuvant therapy (ADJ; n = 8), or palliative therapy (PAL) following failure of multimodal treatment (n = 2), were included.<\/jats:p>\n                    <jats:p>At the last follow-up (mean 7.6 \u00b1 5.3 months), 12 patients showed subtotal response, 3 exhibited partial response, and 1 maintained stable disease. Mean volume reduction was 88.9 \u00b1 4.4%, 73.3 \u00b1 23.4%, and 91.8 \u00b1 4.3% in the NEO, ADJ, and PAL groups, respectively.<\/jats:p>\n                    <jats:p>Targeted therapy resolved headaches in 5\/5 patients and visual impairment in 6\/9; 2\/3 patients had improved neurological symptoms, 1\/4 presented weight loss, and 2\/14 recovered endocrine function.<\/jats:p>\n                    <jats:p>Targeted therapy was well-tolerated in 62.5% of cases; adverse events led to treatment discontinuation in 5 patients and definitive discontinuation in 3 cases.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In this study, 94% of patients showed partial response or better to TT. Adverse events were acceptable. Further research is needed to establish standardized protocols; however, these results advocate for a NEO approach in invasive PCPs.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ejendo\/lvae091","type":"journal-article","created":{"date-parts":[[2024,8,19]],"date-time":"2024-08-19T06:23:48Z","timestamp":1724048628000},"page":"251-261","source":"Crossref","is-referenced-by-count":30,"title":["BRAF and MEK inhibitor targeted therapy in papillary craniopharyngiomas: a cohort study"],"prefix":"10.1093","volume":"191","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5242-1761","authenticated-orcid":false,"given":"Dario","family":"De Alcubierre","sequence":"first","affiliation":[{"name":"Department of Experimental Medicine, Sapienza University of Rome , Rome F-00161 , Italy"},{"name":"Cancer Research Center of Lyon, Inserm U1052, CNRS UMR5286 , Lyon F-69008 , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grigorios","family":"Gkasdaris","sequence":"additional","affiliation":[{"name":"Neurosurgery Department, Reference Center for Rare Pituitary Diseases HYPO, \u201cGroupement Hospitalier Est\u201d Hospices Civils de Lyon , Bron F-69677 , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaux","family":"Mordrel","sequence":"additional","affiliation":[{"name":"CHU de Poitiers, ProDiCeT, Universit\u00e9 de Poitiers , Poitiers F-86073 , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Joncour","sequence":"additional","affiliation":[{"name":"Oncology Department, Poitiers University Hospital , Poitiers F-86000 , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Briet","sequence":"additional","affiliation":[{"name":"CHU d'Angers , Angers F-49100 , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabien","family":"Almairac","sequence":"additional","affiliation":[{"name":"H\u00f4pital Pasteur II, University Hospital of Nice , Nice F-06000 , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Boetto","sequence":"additional","affiliation":[{"name":"Gui de Chauliac Hospital, Montpellier University Medical Center , Montpellier F-34295 , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celine","family":"Mouly","sequence":"additional","affiliation":[{"name":"Endocrinology Department, CHU Toulouse , Toulouse F-31400 , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delphine","family":"Larrieu-Ciron","sequence":"additional","affiliation":[{"name":"Oncology Department, Oncopole Claudius Regaud, Toulouse IUCT Oncopole , Toulouse F-31100 , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre","family":"Vasiljevic","sequence":"additional","affiliation":[{"name":"Centre de Pathologie Est, Groupement Hospitalier Est, Hospices Civils de Lyon , Bron F- 69677 , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Villa","sequence":"additional","affiliation":[{"name":"Department of Neuropathology, H\u00f4pital Universitaire Piti\u00e9-Salp\u00eatri\u00e8re, APHP, Sorbonne Universit\u00e9 , Paris F-75651 , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-8182-5955","authenticated-orcid":false,"given":"Camille","family":"Sergeant","sequence":"additional","affiliation":[{"name":"Endocrinology Department, Reference Center for Rare Pituitary Diseases HYPO, \u201cGroupement Hospitalier Est\u201d Hospices Civils de Lyon , Bron F-69677 , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8150-5785","authenticated-orcid":false,"given":"Fran\u00e7ois","family":"Ducray","sequence":"additional","affiliation":[{"name":"Department of Neuro-Oncology, Groupement Hospitalier Est, Hospices Civils de Lyon , Bron F-69677 , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loic","family":"Feuvret","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Groupement Hospitalier Est, Hospices Civils de Lyon , Bron F-69677 , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Chanson","sequence":"additional","affiliation":[{"name":"Service d\u2019Endocrinologie et des Maladies de la Reproduction et Centre de R\u00e9f\u00e9rence des Maladies Rares de l\u2019Hypophyse HYPO, Universit\u00e9 Paris-Saclay, Inserm, Physiologie et Physiopathologie Endocriniennes, Assistance Publique-H\u00f4pitaux de Paris, H\u00f4pital Bic\u00eatre , Le Kremlin-Bic\u00eatre F-94270 , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0735-8278","authenticated-orcid":false,"given":"Bertrand","family":"Baussart","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, La Piti\u00e9-Salp\u00eatri\u00e8re Hospital, AP- HP, Sorbonne University , Paris F-75651 , France"},{"name":"Universit\u00e9 Paris Cit\u00e9, CNRS, INSERM, Institut Cochin , Paris F-75014 , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9517-338X","authenticated-orcid":false,"given":"Gerald","family":"Raverot","sequence":"additional","affiliation":[{"name":"Cancer Research Center of Lyon, Inserm U1052, CNRS UMR5286 , Lyon F-69008 , France"},{"name":"Endocrinology Department, Reference Center for Rare Pituitary Diseases HYPO, \u201cGroupement Hospitalier Est\u201d Hospices Civils de Lyon , Bron F-69677 , France"},{"name":"Lyon 1 University , Villeurbanne F-69100 , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"Jouanneau","sequence":"additional","affiliation":[{"name":"Cancer Research Center of Lyon, Inserm U1052, CNRS UMR5286 , Lyon F-69008 , France"},{"name":"Neurosurgery Department, Reference Center for Rare Pituitary Diseases HYPO, \u201cGroupement Hospitalier Est\u201d Hospices Civils de Lyon , Bron F-69677 , France"},{"name":"Lyon 1 University , Villeurbanne F-69100 , France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,8,19]]},"reference":[{"issue":"8","key":"2024081910234117200_lvae091-B1","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1093\/neuonc\/nos142","article-title":"Incidence, treatment and survival of patients with craniopharyngioma in the surveillance, epidemiology and end results program","volume":"14","author":"Zacharia","year":"2012","journal-title":"Neuro Oncol"},{"issue":"1","key":"2024081910234117200_lvae091-B2","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/s41572-019-0125-9","article-title":"Craniopharyngioma","volume":"5","author":"M\u00fcller","year":"2019","journal-title":"Nat Rev Dis Primers"},{"issue":"8","key":"2024081910234117200_lvae091-B3","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1007\/s00701-004-0295-3","article-title":"Intraventricular craniopharyngiomas: topographical classification and surgical approach selection based on an extensive overview","volume":"146","author":"Pascual","year":"2004","journal-title":"Acta Neurochir (Wien)"},{"issue":"2","key":"2024081910234117200_lvae091-B4","doi-asserted-by":"crossref","first-page":"381","DOI":"10.3171\/2013.1.JNS111722","article-title":"Displacement of mammillary bodies by craniopharyngiomas involving the third ventricle: surgical-MRI correlation and use in topographical diagnosis","volume":"119","author":"Pascual","year":"2013","journal-title":"J Neurosurg"},{"issue":"12","key":"2024081910234117200_lvae091-B5","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1007\/s00701-011-1149-4","article-title":"Infundibulo-tuberal or not strictly intraventricular craniopharyngioma: evidence for a major topographical category","volume":"153","author":"Pascual","year":"2011","journal-title":"Acta Neurochir (Wien)"},{"issue":"6","key":"2024081910234117200_lvae091-B6","doi-asserted-by":"crossref","first-page":"E13","DOI":"10.3171\/2016.9.FOCUS16304","article-title":"Craniopharyngioma adherence: a comprehensive topographical categorization and outcome-related risk stratification model based on the methodical examination of 500 tumors","volume":"41","author":"Prieto","year":"2016","journal-title":"Neurosurg Focus"},{"issue":"5-6","key":"2024081910234117200_lvae091-B7","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.wneu.2012.07.033","article-title":"Predictive factors for craniopharyngioma recurrence: a systematic review and illustrative case report of a rapid recurrence","volume":"79","author":"Prieto","year":"2013","journal-title":"World Neurosurg"},{"key":"2024081910234117200_lvae091-B8","doi-asserted-by":"crossref","first-page":"e803","DOI":"10.1016\/j.wneu.2019.06.037","article-title":"Is gross total resection reasonable in adults with craniopharyngiomas with hypothalamic involvement?","volume":"129","author":"Apra","year":"2019","journal-title":"World Neurosurg"},{"issue":"15","key":"2024081910234117200_lvae091-B9","doi-asserted-by":"crossref","first-page":"3831","DOI":"10.3390\/cancers14153831","article-title":"The challenging management of craniopharyngiomas in adults: time for a reappraisal?","volume":"14","author":"Cuny","year":"2022","journal-title":"Cancers (Basel)"},{"key":"2024081910234117200_lvae091-B10","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.wneu.2020.05.172","article-title":"Craniopharyngiomas: challenges and controversies","volume":"142","author":"Asha","year":"2020","journal-title":"World Neurosurg"},{"issue":"8","key":"2024081910234117200_lvae091-B11","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","article-title":"The 2021 WHO classification of tumors of the central nervous system: a summary","volume":"23","author":"Louis","year":"2021","journal-title":"Neuro Oncol"},{"issue":"9-10","key":"2024081910234117200_lvae091-B12","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1159\/000506904","article-title":"Biological behaviour of craniopharyngiomas","volume":"110","author":"Martinez-Barbera","year":"2020","journal-title":"Neuroendocrinology"},{"key":"2024081910234117200_lvae091-B13","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-030-41176-3","volume-title":"Adult Craniopharyngiomas: Differences and Lessons from Paediatrics","author":"Jouanneau","year":"2020"},{"issue":"6","key":"2024081910234117200_lvae091-B14","doi-asserted-by":"crossref","first-page":"E2","DOI":"10.3171\/2016.9.FOCUS16325","article-title":"Diagnosis and management of craniopharyngiomas in the era of genomics and targeted therapy","volume":"41","author":"Martinez-Gutierrez","year":"2016","journal-title":"Neurosurg Focus"},{"issue":"12","key":"2024081910234117200_lvae091-B15","doi-asserted-by":"crossref","first-page":"5751","DOI":"10.1210\/jc.2019-01299","article-title":"The medical therapy of craniopharyngiomas: the way ahead","volume":"104","author":"Alexandraki","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2024081910234117200_lvae091-B16","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/ng.2868","article-title":"Exome sequencing identifies BRAF mutations in papillary craniopharyngiomas","volume":"46","author":"Brastianos","year":"2014","journal-title":"Nat Genet"},{"issue":"6","key":"2024081910234117200_lvae091-B17","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1007\/s00401-014-1270-6","article-title":"BRAF V600E mutations are characteristic for papillary craniopharyngioma and may coexist with CTNNB1-mutated adamantinomatous craniopharyngioma","volume":"127","author":"Larkin","year":"2014","journal-title":"Acta Neuropathol"},{"issue":"24","key":"2024081910234117200_lvae091-B18","doi-asserted-by":"crossref","first-page":"3221","DOI":"10.2217\/fon.15.233","article-title":"Is there a role for targeted medical therapies in patients with craniopharyngiomas?","volume":"11","author":"Tritos","year":"2015","journal-title":"Future Oncol"},{"issue":"3","key":"2024081910234117200_lvae091-B19","doi-asserted-by":"crossref","first-page":"515","DOI":"10.3390\/brainsci13030515","article-title":"Current advances in papillary craniopharyngioma: state-of-the-art therapies and overview of the literature","volume":"13","author":"Jannelli","year":"2023","journal-title":"Brain Sci"},{"issue":"9992","key":"2024081910234117200_lvae091-B20","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/S0140-6736(15)60898-4","article-title":"Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial","volume":"386","author":"Long","year":"2015","journal-title":"Lancet"},{"issue":"6","key":"2024081910234117200_lvae091-B21","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.3171\/2019.8.JNS19643","article-title":"Dual BRAF\/MEK therapy in BRAF V600E-mutated primary brain tumors: a case series showing dramatic clinical and radiographic responses and a reduction in cutaneous toxicity","volume":"133","author":"Bernstein","year":"2019","journal-title":"J Neurosurg"},{"key":"2024081910234117200_lvae091-B22","doi-asserted-by":"crossref","first-page":"882381","DOI":"10.3389\/fendo.2022.882381","article-title":"Neoadjuvant B-RAF and MEK inhibitor targeted therapy for adult papillary craniopharyngiomas: a new treatment paradigm","volume":"13","author":"Calvanese","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"2","key":"2024081910234117200_lvae091-B23","doi-asserted-by":"crossref","first-page":"95","DOI":"10.2217\/cns-2016-0034","article-title":"BRAF-V600E mutant papillary craniopharyngioma dramatically responds to combination BRAF and MEK inhibitors","volume":"6","author":"Roque","year":"2017","journal-title":"CNS Oncol"},{"issue":"17","key":"2024081910234117200_lvae091-B24","doi-asserted-by":"crossref","first-page":"2910","DOI":"10.1002\/cncr.32197","article-title":"Targeted treatment of papillary craniopharyngiomas harboring BRAF V600E mutations","volume":"125","author":"Juratli","year":"2019","journal-title":"Cancer"},{"issue":"1","key":"2024081910234117200_lvae091-B25","first-page":"vdaa141","article-title":"Medical debulking with BRAF\/MEK inhibitors in aggressive BRAF-mutant craniopharyngioma","volume":"2","author":"Di Stefano","year":"2020","journal-title":"Neurooncol Adv"},{"issue":"11","key":"2024081910234117200_lvae091-B26","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1007\/s00701-017-3311-0","article-title":"Recurrent papillary craniopharyngioma with BRAFV600E mutation treated with neoadjuvant-targeted therapy","volume":"159","author":"Rostami","year":"2017","journal-title":"Acta Neurochir (Wien)"},{"issue":"57","key":"2024081910234117200_lvae091-B27","doi-asserted-by":"crossref","first-page":"6038","DOI":"10.18632\/oncotarget.27203","article-title":"Newly diagnosed papillary craniopharyngioma with BRAF V600E mutation treated with single-agent selective BRAF inhibitor dabrafenib: a case report","volume":"10","author":"Rao","year":"2019","journal-title":"Oncotarget"},{"issue":"2","key":"2024081910234117200_lvae091-B28","doi-asserted-by":"crossref","first-page":"djv310","DOI":"10.1093\/jnci\/djv310","article-title":"Dramatic response of BRAF V600E mutant papillary craniopharyngioma to targeted therapy","volume":"108","author":"Brastianos","year":"2016","journal-title":"J Natl Cancer Inst"},{"issue":"12","key":"2024081910234117200_lvae091-B29","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.6004\/jnccn.2020.7624","article-title":"Successful use of BRAF\/MEK inhibitors as a neoadjuvant approach in the definitive treatment of papillary craniopharyngioma","volume":"18","author":"Khaddour","year":"2020","journal-title":"J Natl Compr Canc Netw"},{"issue":"4","key":"2024081910234117200_lvae091-B30","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.3171\/2017.11.JNS172373","article-title":"Recurrent papillary craniopharyngioma with BRAF V600E mutation treated with dabrafenib: case report","volume":"130","author":"Himes","year":"2018","journal-title":"J Neurosurg"},{"issue":"5","key":"2024081910234117200_lvae091-B31","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1007\/s11102-015-0663-4","article-title":"Pronounced response of papillary craniopharyngioma to treatment with vemurafenib, a BRAF inhibitor","volume":"19","author":"Aylwin","year":"2016","journal-title":"Pituitary"},{"issue":"2","key":"2024081910234117200_lvae091-B32","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1056\/NEJMoa2213329","article-title":"BRAF-MEK Inhibition in newly diagnosed papillary craniopharyngiomas","volume":"389","author":"Brastianos","year":"2023","journal-title":"N Engl J Med"},{"issue":"3","key":"2024081910234117200_lvae091-B33","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.3390\/curroncol29030138","article-title":"Current advances in the management of adult craniopharyngiomas","volume":"29","author":"Lara-Velazquez","year":"2022","journal-title":"Curr Oncol"},{"issue":"5","key":"2024081910234117200_lvae091-B34","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.4103\/sja.SJA_543_18","article-title":"The STROBE guidelines","volume":"13","author":"Cuschieri","year":"2019","journal-title":"Saudi J Anaesth"},{"key":"2024081910234117200_lvae091-B35","doi-asserted-by":"crossref","first-page":"e1245","DOI":"10.1016\/j.wneu.2018.09.053","article-title":"Craniopharyngiomas primarily involving the hypothalamus: a model of neurosurgical lesions to elucidate the neurobiological basis of psychiatric disorders","volume":"120","author":"Pascual","year":"2018","journal-title":"World Neurosurg"},{"issue":"2","key":"2024081910234117200_lvae091-B36","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/s10143-018-1010-9","article-title":"Craniopharyngioma adherence: a reappraisal of the evidence","volume":"43","author":"Prieto","year":"2020","journal-title":"Neurosurg Rev"},{"issue":"2","key":"2024081910234117200_lvae091-B37","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1093\/neuros\/nyy569","article-title":"A clinical rule for preoperative prediction of BRAF mutation status in craniopharyngiomas","volume":"85","author":"Fujio","year":"2019","journal-title":"Neurosurgery"},{"issue":"6","key":"2024081910234117200_lvae091-B38","doi-asserted-by":"crossref","first-page":"3411","DOI":"10.1007\/s10143-021-01510-8","article-title":"Stereotactic cysto-ventricular catheters in craniopharyngiomas: an effective minimally invasive method to improve visual impairment and achieve long-term cyst volume reduction","volume":"44","author":"Steiert","year":"2021","journal-title":"Neurosurg Rev"},{"issue":"20","key":"2024081910234117200_lvae091-B39","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1056\/NEJMoa1406037","article-title":"Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma","volume":"371","author":"Long","year":"2014","journal-title":"N Engl J Med"},{"issue":"20","key":"2024081910234117200_lvae091-B40","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1056\/NEJMoa1408868","article-title":"Combined vemurafenib and cobimetinib in BRAF-mutated melanoma","volume":"371","author":"Larkin","year":"2014","journal-title":"N Engl J Med"},{"issue":"18","key":"2024081910234117200_lvae091-B41","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1056\/NEJMoa1210093","article-title":"Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations","volume":"367","author":"Flaherty","year":"2012","journal-title":"N Engl J Med"},{"issue":"2","key":"2024081910234117200_lvae091-B42","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1056\/NEJMe2305288","article-title":"Precision oncology for papillary craniopharyngioma","volume":"389","author":"Blakeley","year":"2023","journal-title":"N Engl J Med"}],"container-title":["European Journal of Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ejendo\/article-pdf\/191\/2\/251\/58849976\/lvae091.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ejendo\/article-pdf\/191\/2\/251\/58849976\/lvae091.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,19]],"date-time":"2024-08-19T06:24:04Z","timestamp":1724048644000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ejendo\/article\/191\/2\/251\/7735740"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":42,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,8,5]]}},"URL":"https:\/\/doi.org\/10.1093\/ejendo\/lvae091","relation":{},"ISSN":["0804-4643","1479-683X"],"issn-type":[{"value":"0804-4643","type":"print"},{"value":"1479-683X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,8]]},"published":{"date-parts":[[2024,8]]}}}